Brief description of the entity

LINCBIOTECH is a new brand spin-off from the Clinic Hospital of Santiago de Compostela (Galicia, Spain). We are devoted to the challenging task of developing innovative solutions for an enhanced clinical management of patients who suffer from highly prevalent neurological diseases such as stroke and Alzheimer’s disease. One of our products, LINCNEURO, consists of a clinical decision support system (CDSS) that provides useful insights to clinicians for an enhanced clinical management of stroke patients. In addition, we are developing a next generation of monoclonal antibodies (high affinity to several Tau species) with multiple applications in the diagnosing and treating AD

Activities and services offered

Clinical decision system to enhance the clinical management of patients that have suffered a stroke -In vitro diagnosis kit to discriminate between patients with mild cognitive decline and Alzheimer’s disease.

The differentiating value

Proprietary software technology, highly-skilled team

Your role in neuroATLANTIC project

Development of novel images techniques for an enhanced diagnosis of stroke during the acute phase

The results you expect to achieve

Novel neuroimaging biomarker for stroke

Your thoughts about the importance and the opportunity this project represents and your main goal by participating in it

This project gives us the opportunity to collaborate with a high-level multidisciplinary consortium comprised of multiple top-notch research and clinical centres. This will help us in accelerating the development and market uptake of our projects.

Your thoughts about the impact that this project will have on the ecosystem

This project will contribute to increase the capabilities in the cooperation area to better diagnose and treat neurological diseases

Contact Info

Juan Ruiz-Constantino
CEO